For the year ending 2025-12-31, VYNE made $570K in revenue. -$26,501K in net income. Net profit margin of -4649.30%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenues | 570 | 501 | ||
| Research and development | 19,237 | 30,946 | ||
| General and administrative | 11,082 | 13,192 | ||
| Total operating expenses | 30,319 | 44,138 | ||
| Operating loss | -29,749 | -43,637 | ||
| Other income, net | 3,017 | 3,834 | ||
| Loss from continuing operations before income taxes | -26,732 | -39,803 | ||
| Income tax expense | 4 | 4 | ||
| Loss from continuing operations | -26,736 | -39,807 | ||
| Product sales, net-Product | 273 | - | ||
| General and administrative | 20 | - | ||
| Total operating expenses | 20 | - | ||
| Income (loss) from discontinued operations, before taxes | 253 | - | ||
| Income tax expense | 0 | - | ||
| Income (loss) from discontinued operations, net of income taxes | 253 | -27 | ||
| Net loss | -26,483 | -39,834 | ||
| Unrealized losses on marketable securities, net of tax of 0 | -18 | -6 | ||
| Total other comprehensive loss | -18 | -6 | ||
| Comprehensive loss | -26,501 | -39,840 | ||
| Basic EPS | -0.62 | -0.93 | ||
| Diluted EPS | -0.62 | -0.93 | ||
| Basic Average Shares | 42,768,000 | 42,589,000 | ||
| Diluted Average Shares | 42,768,000 | 42,589,000 | ||
VYNE Therapeutics Inc. (VYNE)
VYNE Therapeutics Inc. (VYNE)